Precision BioSciences announced the dosing of the first patient in its Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for Duchenne muscular dystrophy. The treatment was administered at Arkansas Children’s Hospital, a designated care center. PBGENE-DMD utilizes the company's ARCUS platform to excise exons 45-55 of the dystrophin gene in patients with specific mutations, aiming to restore near full-length functional dystrophin protein. Initial safety data is expected by year-end 2026. Precision BioSciences operates as a clinical-stage biotechnology company developing in vivo gene editing therapies using its proprietary ARCUS platform.

Precision BioSciences reported second quarter 2026 financial results with a net loss of $32.7 million, or $(1.26) per share, driven by a non-cash warrant liability adjustment. The company held $112.4 million in cash as of June 30, 2026, sufficient to fund operations through 2028. In the PBGENE-HBV program, biopsy data showed a 1-log reduction in cccDNA and sustained pgRNA loss in all evaluable patients. The PBGENE-DMD trial is actively recruiting at two sites. Additionally, Precision received a $7.5 million clinical milestone payment from TG Therapeutics and announced executive promotions for Naresh Tanna as CFO and Alex Kelly as COO. Precision BioSciences operates in the biotechnology industry, developing in vivo gene editing therapies using its ARCUS platform.

Precision BioSciences, Inc. announced several senior leadership changes effective August 1, 2026, including the promotion of Alex Kelly from Chief Financial Officer to Chief Operating Officer and the appointment of Naresh Tanna as Chief Financial Officer. Additionally, Mei Burris was designated as Chief Accounting Officer and principal accounting officer. The company is a clinical-stage gene editing company developing in vivo gene editing therapies for high unmet need diseases.

Precision BioSciences, Inc. reported clinical highlights from its ELIMINATE-B study for chronic hepatitis B, showing a 1-log reduction in cccDNA-derived transcripts via PBGENE-HBV. The company also announced the activation of a second clinical site at Washington University School of Medicine for its FUNCTION-DMD clinical trial. Precision BioSciences, Inc. is a biotechnology company focused on developing gene editing technologies for therapeutic use.

Precision BioSciences, Inc. entered into a First Amendment to its Amended and Restated Loan and Security Agreement with Banc of California on June 10, 2026, which extended the maturity date of its Term Loan from June 30, 2027, to December 31, 2029. Precision BioSciences, Inc. is a biotechnology company focused on development and commercialization of gene editing technologies.